Medicinova
Presence
Medicinova is a company listed under the stock ticker MNOV (US).
Executives
View the org chart displaying its 8 main executives
Most searched biographies at Medicinova
- Yuichi Iwaki, Director, President and Chief Executive Officer
- Hideki Nagao, Director
- Jeff Himawan, Chairman of the Board
Create your alert
to follow the executive moves at Medicinova.
Biotechnology
Medicinova has 2,280 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Medicinova
- MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology | MediciNova, Inc.
- MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada | MediciNova, Inc.
- MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria | MediciNova, Inc.
- MediciNova Receives Gene Therapy Milestone Payment | MediciNova, Inc.
- MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury | MediciNova, Inc.
- MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe | MediciNova, Inc.
- MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe | MediciNova, Inc.
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology | MediciNova, Inc.
- MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe | MediciNova, Inc.
- MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting | MediciNova, Inc.
- View more press releases Close
Social media about Medicinova
- Medicinova on Wikipedia, Google News & Yahoo Finance
- Medicinova on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Yuichi Iwaki 
